Copyright

*©2016 Cotiviti Corporation, all rights reserved. All confidential, proprietary information, names and logos contained herein shall at all times be and remain the sole and exclusive property of Cotiviti Corporation and its wholly owned subsidiaries.*

*CPT only copyright 2016 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.*

# factor ix, (antihemophilic factor, recombinant), Rixubis #

Brand name: RIXUBIS (COAGULATION FACTOR IX RECOMBINANT HUMAN) KIT

J7200 (Injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu)

Version: 1

Release Date: unreleased

  


<table> 
 <thead> 
  <tr> 
   <th>Item</th> 
   <th>Item Details</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>[HCPCS] (Descriptor)</td> 
   <td>
    <div>
     J7200
    </div>
    <div>
     (Injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu)
    </div></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Route of administration</td> 
   <td></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Time of administration</td> 
   <td></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Administration codes</td> 
   <td></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>How supplied</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### References ###

<table> 
 <thead> 
  <tr> 
   <th>Reference type</th> 
   <th>Reference details</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>Drug Label</td> 
   <td>Drug Label, RIXUBIS (factor ix, (antihemophilic factor, recombinant), Rixubis), January 2016<br />Drug Label, Rixubuis (factor ix, (antihemophilic factor, recombinant), Rixubis), January 2016<br />Drug Label, RIXUBIS (factor ix, (antihemophilic factor, recombinant), Rixubis), January 2016<br /></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Clinical Pharmacology</td> 
   <td>Clinical Pharmacology, factor ix, (antihemophilic factor, recombinant), Rixubis, May 2015<br /></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Micromedex DrugDex</td> 
   <td>Micromedex DrugDex, factor ix, (antihemophilic factor, recombinant), Rixubis, November 2016<br /></td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>Lexi-Drugs</td> 
   <td>Lexi-Drugs, factor ix, (antihemophilic factor, recombinant), Rixubis, November 2016<br /></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### LCDs ###

<table> 
 <thead> 
  <tr> 
   <th>LCD</th> 
   <th>MAC name</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>A/BMAC/J-N/L33684/R-01-01-2017</td> 
   <td> First Coast Service Options, Inc. </td> 
   <td></td> 
  </tr> 
  <tr> 
   <td>A/BMAC/J-H,J-L/L35111/R-10-01-2016</td> 
   <td> Novitas Solutions, Inc. </td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Medical journal ###

<table> 
 <thead> 
  <tr> 
   <th>Citation</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>&nbsp;</td> 
   <td>&nbsp;</td> 
  </tr> 
 </tbody> 
</table>

### Notes ###

<table> 
 <thead> 
 </thead> 
 <tbody> 
  <tr> 
   <td>&nbsp;</td> 
  </tr> 
  <tr> 
   <td>&nbsp;</td> 
  </tr> 
 </tbody> 
</table>

### Indications ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>&nbsp;Drug Label&nbsp;</th> 
   <th>&nbsp;Clinical Pharmacology&nbsp;</th> 
   <th>&nbsp;Micromedex DrugDex&nbsp;</th> 
   <th>&nbsp;NCCN&nbsp;</th> 
   <th>&nbsp;Lexi-Drugs&nbsp;</th> 
   <th>&nbsp;AHFS-DI&nbsp;</th> 
   <th>&nbsp;Other&nbsp;</th> 
   <th>&nbsp;CMS Policy&nbsp;</th> 
   <th>&nbsp;LCD&nbsp;</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>Hemophilia B</td> 
   <td align="center"> x </td> 
   <td align="center"> x </td> 
   <td align="center"> x </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> </td> 
   <td align="center"> x </td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Diagnosis codes ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>NCCN ICD-10</th> 
   <th>LCD ICD-10</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>Hemophilia B</td> 
   <td></td> 
   <td>D67</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Diagnosis code Summary ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>ICD-10 codes</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>Hemophilia B</td> 
   <td>D67</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Diagnosis code Overlaps ###

<table> 
 <thead> 
  <tr> 
   <th>ICD-10 Code</th> 
   <th>Indication</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Manifestation Codes ###

<table> 
 <thead> 
  <tr> 
   <th>ICD-10 Code(s)</th> 
   <th>Indication</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Dosing Patterns ###

### Daily Maximum Dose ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Maximum dose</th> 
   <th>Maximum Units</th> 
  </tr> 
 </thead> 
 <tbody> 
 </tbody> 
</table>

### Maximum Frequency ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Days</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Age ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Age</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Gender ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Gender</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Visits over time ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Visits</th> 
   <th>Interval</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Units over time ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Units</th> 
   <th>Interval</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Combination therapy ###

<table> 
 <thead> 
  <tr> 
   <th>Indication</th> 
   <th>Combination</th> 
   <th>HCPCS</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td>NA</td> 
   <td></td> 
   <td></td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### Global Review ###

<table> 
 <thead> 
  <tr> 
   <th>Current indication</th> 
   <th>Global review indication</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td></td> 
   <td>Hemophilia B</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

  


<table> 
 <thead> 
  <tr> 
   <th>Current ICD-10 codes</th> 
   <th>Global review ICD-10 codes</th> 
   <th>Comment</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr> 
   <td></td> 
   <td>D67</td> 
   <td></td> 
  </tr> 
 </tbody> 
</table>

### factor ix, (antihemophilic factor, recombinant), Rixubis rules ###

<table> 
 <thead> 
  <tr> 
   <th>Mid Rule</th> 
   <th>Description</th> 
   <th>Comments</th> 
  </tr> 
 </thead> 
 <tbody> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7200&gt; is billed and a diagnosis of Hemophilia B is not present on the claim header, then deny J7200 with reason The Diagnosis Codes On The Claim Do Not Support The Billed Procedure Code. Diagnosis code: ICD-10 code: D67 <h3>Script</h3> The billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), was denied because it was not reported with an approved diagnosis code, per our policy, which is based on the FDA-approved package insert/prescribing information and the pharmaceutical compendia. <h3>Rationale</h3> According to our policy, which is based on the FDA-approved package insert/prescribing information and the pharmaceutical compendia, factor ix, (antihemophilic factor, recombinant), Rixubis is appropriate for certain FDA-approved indications. Label indication: Hemophilia B <h3>Reference</h3> Drug Label, RIXUBIS (factor ix, (antihemophilic factor, recombinant), Rixubis), January 2016; Drug Label, RIXUBIS (factor ix, (antihemophilic factor, recombinant), Rixubis), January 2016; Clinical Pharmacology, factor ix, (antihemophilic factor, recombinant), Rixubis, May 2015; Micromedex DrugDex, factor ix, (antihemophilic factor, recombinant), Rixubis, November 2016; Lexi-Drugs, factor ix, (antihemophilic factor, recombinant), Rixubis, November 2016; LCD: A/BMAC/J-N/L33684/R-01-01-2017; A/BMAC/J-H,J-L/L35111/R-10-01-2016 </td>
   <td></td>
  </tr> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7200&gt; is billed with units greater than 34,080 by any provider and any claim type and a diagnosis of Hemophilia B is present on the claim header, then adjust units to not exceed the maximum allowed per date of service (34,080 units of J7200) with reason Adjusted Units Because They Exceeded The Amount Allowed. Diagnosis code: ICD-10 code: D67 <h3>Script</h3> The units for the billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), were adjusted because they exceeded the maximum allowed for a single date of service for the reported condition, per our policy, which is based on the FDA-approved package insert/prescribing information and the pharmaceutical compendia. <h3>Rationale</h3> According to our policy, which is based on the FDA-approved package insert/prescribing information and the pharmaceutical compendia, the maximum recommended daily dosage for factor ix, (antihemophilic factor, recombinant), Rixubis for the reported indication is 300 iu/kg (34,080 iu or 34,080 units of J7200 for a 250 lb/113.6 kg/2.45 m2 patient). Therefore, the additional units have been denied. <h3>Reference</h3> Drug Label, RIXUBIS (factor ix, (antihemophilic factor, recombinant), Rixubis), January 2016; Clinical Pharmacology, factor ix, (antihemophilic factor, recombinant), Rixubis, May 2015; Micromedex DrugDex, factor ix, (antihemophilic factor, recombinant), Rixubis, November 2016; Lexi-Drugs, factor ix, (antihemophilic factor, recombinant), Rixubis, November 2016 <h3>SubRule Note</h3> 100 iu/kg every 8 hours.. </td>
   <td></td>
  </tr> 
  <tr>
   <td></td>
   <td> <br /> <h3>Description</h3> If &lt;CL_J7200&gt; is billed with modifier JW (Drug amount discarded/not administered to any patient) and the units equal or exceed 250, then deny J7200-JW with reason Procedure Inappropriately Coded. <h3>Script</h3> The billed drug code, &lt;CPT&gt; (&lt;CPT_DESC&gt;), was denied because it was submitted with modifier JW (Drug amount discarded/not administered to any patient) and the units equaled or exceeded 250, per our policy, which is based on CMS Policy and the FDA-approved package insert/prescribing information. <h3>Rationale</h3> According to our policy, which is based on CMS Policy and the FDA-approved package insert/prescribing information, factor ix, (antihemophilic factor, recombinant), Rixubis is supplied in 250, 500, 1000, 2000, and 3000 iu single-use vials. It is expected that a provider will use a combination of vial sizes that eliminates or minimizes drug wastage. <h3>Reference</h3> IOM 100-04, Chapter 17, Section 40; Drug Label, Rixubuis (factor ix, (antihemophilic factor, recombinant), Rixubis), January 2016 </td>
   <td></td>
  </tr> 
 </tbody> 
</table>

  
dosage rule per indication enabled: true

  
generated on: Apr 10, 2017 12:36:38 PM  
